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Abstract: Anthrax, a zoonotic disease that primarily affects herbivores, has received recent 
attention as a potential agent of bioterrorism. We report a patient who presented with a 4-day 
history of pain, watering and difficulty in opening the left upper and lower eyelids, and fever. 
Clinical examination revealed brawny nonpitting edema with serosanguinous discharge. The 
history of the death of his sheep 1 week prior to the illness provided the clue to the diagnosis. 
Although standard cultures of the blood and the serous fluid from the lesion were negative, prob-
ably as a result of prior treatment, the diagnosis of cutaneous anthrax was made by a polymerase 
chain reaction (PCR) test of the serous fluid. Serial photographs demonstrating resolution of 
the lesion with appropriate antibiotic therapy are presented.
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Introduction
Anthrax, a zoonotic disease caused by Bacillus anthracis (B. anthracis), primarily 
affects herbivores including sheep, cattle, horses, and other domestic animals.1 Humans 
may be affected as a result of exposure to an infected animal or animal products. This 
organism has received recent attention as a potential agent of bioterrorism.1 Three 
forms are described: cutaneous, inhalational, and gastrointestinal.1 We describe a 
patient with oculocutaneous anthrax.
Case description
A 39-year-old male presented to our outpatient clinic with a 4-day history of fever and 
swelling of the left upper and lower eyelids associated with pain, watering, and difficulty 
in opening the eyelids. He reported that his sheep had died suddenly 1 week prior to 
his illness. There was no past history of any medical illness. The patient reported that 
he was prescribed tablets and injections by a general practitioner, but was unable to 
provide details of this treatment to us.
On examination, there was brawny nonpitting edema of the upper and lower eye-
lids of the left eye and left side of the face (Figure 1). There was an ulceration and 
black discoloration along the left lower lid margin with serosanguinous discharge. 
His visual acuity was 20/20 in both the eyes. The anterior and posterior segments of 
both the eyes were within normal limits. A diagnosis of oculocutaneous anthrax was 
considered based on the history and clinical findings. Serous fluid from the eyelid 
and blood were collected and sent for conventional cultural methods and polymerase 
chain reaction (PCR) test. The Gram stain of the serous fluid revealed no leucocytes or Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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bacteria. Cultures of the serous fluid and blood were   negative 
for B. anthracis.
PCR method for the detection  
of B. anthracis
The patient’s DNA was extracted using the QIA amp DNA 
blood mini kit (QIAGEN, Hilden, Germany) according to 
the manufacturer’s instruction. A 596-bp fragment of the 
protective antigen (PA) gene, PA (F)-TCC TAA CAC TAA 
CGA AGT CG and PA (R)-GAG GTA GAA GGA TAT ACG 
GT and a 846-bp fragment of the capsule (CAP) gene, CAP 
(F)-CTG AGC CAT TAA TCG ATA TG and CAP (R)2,3 of 
B. anthracis were used as the target for anthrax PCR. The 
DNA was amplified in a total volume of 50 µL with the above 
mentioned primers, 200 µm (each) deoxynucleotide triphos-
phates, 1X PCR buffer, 1.5 mM MgCL2 and 2.5 units of 
Taq polymerase (Amplitaq Gold-Applied Biosystems, 
California, USA) and followed by the addition of 5 µL of 
the template DNA. Thermal cycling was performed at 94°C 
for 5 minutes (initial denaturation) followed by 35 cycles 
at 94°C for 1 minute, 52°C for 1 minute (annealing), 72°C 
for 2 minutes (extension) and the final extension at 72°C 
for 5 minutes; cooled to 4°C.4 Thermal cycling was done 
in the Gene AMP PCR system 9200 (Applied Biosystems, 
California, USA).
A 15 µL portion of the PCR product and 5 µL of 10% 
tracking dye (0.02% xylene cyanol, 0.02% bromophenol 
blue and 50% glycerol) was added to the PCR tube. Fifteen 
microliters of this mix were loaded into the wells in the aga-
rose (Amersham Pharmacia, New Jersey, USA). The PCR 
products were analyzed by submarine gel   electrophoresis 
through a 1% agarose gel in 1X TAE buffer. The gel was 
run at 120 volts for 60 minutes, stained with 0.5 µg/mL 
of ethidium bromide (Amersham Pharmacia, New Jersey, 
USA), visualized and recorded under UV4 in the Gel Doc 
2000 System (Bio-Rad, California, USA). The Gene RulerTM 
100-bp (3000–100bp) DNA Ladder Plus (MBI Fermentas, 
USA) was used as the molecular standard. The PCR from 
the fluid and the blood were positive for the gene encoding 
the protective antigen (PA gene) and the capsule (CAP gene) 
of B. anthracis (Figure 2).
Clinical course of the patient
The patient was started on injection crystalline penicillin, 
2 million international units (1250 mg) every 2 hours intra-
venously. No topical therapy was prescribed, however, the 
patient was given anti-inflammatory agents (ibuprofen). The 
patient responded well to antibiotic therapy with reduction 
of fever and lid edema. A black eschar developed within a 
few days of treatment (Figure 3). On completion of a 10-day 
course of intravenous antibiotics, he was discharged on 
oral penicillin G 500 mg every 6 hours. The total duration 
of antibiotic therapy including intravenous antibiotics was 
6 weeks. Although the eschar reduced in size over time, it 
was firmly adhered to the underlying tissue. When the eschar 
was removed after 1 month of the onset of illness, an ulcer-
ated undersurface was observed (Figure 4). The ulceration 
healed over the next 2 weeks with scarring and ectropion of 
the left lower lid (Figure 5). The low grade lid edema and 
mechanical ptosis of the left upper eyelid resolved over the 
next few weeks.
Figure 1 Brawny nonpitting edema of the upper and lower eyelids of the left eye 
with serosanguinous discharge
Figure 2 Gel electrophoresis for B. anthracis.
Notes: Lane 1 and 9- PA and CAP (positive control); Lane 2 and 10- PA and 
CAP (negative control); Lane 3 and 11- undiluted DNA for PA and CAP (serous 
fluid); Lane 4 and 12- 1/10 diluted DNA for PA and CAP (serous fluid); Lane 5 and 
13- water blank; Lane 6 and 14- undiluted DNA for PA and CAP (blood); Lane 7 
and 15- 1/10 diluted DNA for PA and CAP; Lane 8- marker (100-bp ladder).Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Comments
B. anthracis is commonly found in agricultural environments. 
It is a Gram-positive, aerobic, endospore-forming bacilli 
that, in the vegetative form, has a poor survival rate outside 
an animal or human host.5 It is capable of producing fatal 
infection in livestock and in humans.1 Anthrax is considered 
to be one of most dangerous biological weapons.6 Humans 
are infected when spores are introduced into the body by 
contact with infected animals or animal products.1 Cutaneous 
anthrax has been reported to occur as preseptal cellulitis in 
the eyelids.7,8 Cutaneous anthrax, if untreated, leads to life-
threatening septicemia.1
This report highlights that a high index of clinical sus-
picion and prompt institution of appropriate therapy are 
essential for a successful outcome. Since lesions can become 
sterile within 24 hours of antimicrobial therapy,   confirmation 
of diagnosis can be made using PCR,2–4,9 as was done in 
our patient, when the conventional cultural methods fail to 
identify the etiology or when patients have already received 
antimicrobial therapy.
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Figure 3 Black eschar involving the left lower lid with residual edema of the left 
upper lid.
Figure 4 Ulcerated undersurface of the left lower lid on removal of the eschar.
Figure 5 scarring and ectropion of the left lower lid.Clinical Ophthalmology
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